iBio Expands Antibody Development and Production Services to Include Fc Fusion Therapeutics


IBIO, INC. (“iBio”) announced the expansion of its CDMO capabilities and services to include the development and cGMP manufacturing of Fc fusion proteins for therapeutic pharmaceutical applications.

De-Risk Your Development Program


The “Lab to Launch” time is critical in the highly competitive biotherapeutics development business. Rapid assessment of proven expression systems can reduce your “time to clinic” and “time to market”. iBio is offering a system that can rapidly develop both product and process. iBio can rapidly provide alternate product candidates for rapid comparison and down selection of products that offer superior performance and cost of production. Scale-up is seamless, dependable, and capacity is in place.


Market Data copyright © 2018 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.